Company intelligence / Profile preview
Tecnifar
Lisbon, Portugaltecnifar.pt ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Tecnifar is engaged in the research, development, production, and commercialization of proprietary and licensed drugs focused on several therapeutic areas. The company has clinical-stage programs, notably a Phase 2 candidate (TP-102, a bacteriophage therapy for diabetic foot infection, originally from TechnoPhage) and various marketed products in cardiovascular, CNS, respiratory, urology, and other specialties.
- Therapeutic areas
- Infectious DiseasesEndocrinologyDermatologyNeurology
- Modalities
- Small moleculeBacteriophage therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
TechnoPhage
Beyond the preview
Go deeper on Tecnifar.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tecnifar.